Search | Clinical Trials Finder

Conditions: Androgenetic Alopecia
Interventions: TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System; Device
Lead sponsor: Apira Science, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Androgenetic Alopecia
Interventions: iRestore Hair Rejuvenation System, sham device; Device
Lead sponsor: Freedom Laser Therapy, Inc.; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Androgenetic Alopecia
Interventions: Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 6
States / cities: Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more

Conditions: Alopecia
Interventions: Setipiprant, Placebo, Finasteride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more

Conditions: Androgenetic Alopecia
Interventions: 5% Minoxidil Topical Foam, Vehicle Topical Foam; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more

Conditions: Androgenetic Alopecia
Interventions: 5% minoxidil topical foam; Drug
Lead sponsor: Applied Biology, Inc.; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Tucson, Arizona • Nashville, Tennessee

Conditions: Androgenetic Alopecia
Interventions: minoxidil; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 15 Years to 49 Years · Male only
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Vallejo, California + 12 more

Conditions: Androgenetic Alopecia
Interventions: Autologous platelet-rich plasma; Biological
Lead sponsor: Santiste Medical Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions: VDPHL01 QD, Placebo, VDPHL01 BID; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more

Conditions: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel; Drug
Lead sponsor: Pelage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more

Conditions: Female Pattern Baldness
Interventions: 1550nm non-ablative fractional laser, 1927 thulium fractional laser; Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Androgenetic Alopecia
Interventions: Autologous Platelet Rich Plasma, Saline solution injection; Device
Lead sponsor: Regen Lab SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Androgenetic Alopecia
Interventions: Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution; Biological · Drug
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Marriottsville, Maryland

Conditions: Female Androgenetic Alopecia
Interventions: 5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Androgenetic Alopecia
Interventions: X5 HairLaser, X5 Hair Laser Sham Device; Device
Lead sponsor: Spencer Forrest, Inc.; Industry
Eligibility: 20 Years to 60 Years · Male only
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Hot Springs, Arkansas • St. Petersburg, Florida • New York, New York

Conditions: Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
Interventions: HairMax LaserComb 2009 model 12 beam, Sham Device; Device
Lead sponsor: Lexington International, LLC; Industry
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Miami, Florida • Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 2
States / cities: Paramus, New Jersey • Norfolk, Virginia

Conditions: Female Pattern Alopecia
Interventions: Erchonia MLS; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evans, Georgia

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical Vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Treatment of Androgenetic Alopecia in Males and Females

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

Clinical Trial in Females for Female Pattern Hair Loss

Minoxidil Response Testing in Males With Androgenetic Alopecia

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

Activated PRP for Treatment of Androgenetic Alopecia

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

XVIE to Treat Androgenetic Alopecia (AGA)

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males

Treatment of Androgenetic Alopecia in Females, 12 Beam

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia